Regulation of the leukotriene biosynthetic pathway

M. PETERS-GOLDEN

Division of Pulmonary and Critical Care Medicine, University of Michigan Health System, Ann Arbor, Michigan, USA

Introduction

Leukotrienes (LTs) are potent autocrine and paracrine mediators of diverse cellular processes with critical roles in both homeostasis and disease states. They are synthesized predominantly by leukocytes via the 5-lipoxygenase (5-LO) pathway of arachidonic acid (AA) metabolism. In view of the importance of LT actions, substantial effort has been directed at understanding the biochemical, molecular and cellular aspects of this pathway. This brief review will summarize our current knowledge of the mechanisms by which the key enzymatic steps in this biosynthetic pathway are regulated.

Overview of LT synthesis

LT synthesis can be triggered by a variety of stimuli, including antigens, microbes, cytokines, complement, oxidants, peptides, immune complexes and model agonists such as calcium ionophores. These activate signal transduction cascades that in turn activate LT-forming enzymes. The enzymatic steps in LT biosynthesis are now well understood and are depicted in Fig. 1.

Briefly, a phospholipase A₂ (PLA₂), probably the cytosolic (cPLA₂) or secretory (sPLA₂) isoform, initiates the pathway by catalysing the hydrolysis of AA from membrane phospholipids. The liberated free AA is then oxygenated at C-5 and subsequently dehydrated by the actions of the 5-LO enzyme itself to yield the epoxide intermediate, LTA₄. The efficient utilization of endogenous AA by 5-LO requires a helper protein, termed 5-LO activating protein (FLAP). LTA₄ can then be hydrolysed by LTA₄ hydrolyase to LTE₄, which has potent chemotactic and leukocyte-activating effects, or conjugated with reduced glutathione by LTC₄ synthase to yield LTC₄; the latter can be further modified extracellularly by sequential amino acid removal to yield LTD₄ and LTE₄. Collectively, LTs C₄, D₄ and E₄ are known as cysteinyL LTs (Cys-LTs) and comprise the myotropic and oedemagenic activities long known as ‘slow-reacting substance’.

Regulation of LT synthesis

Many endogenous and exogenous substances can modulate the capacity for LT synthesis by agonist-stimulated leukocytes. Among the substances known to enhance LT generation are vitamin D₃, phorbol esters, endothelin, platelet activating factor and a large variety of cytokines; these include interferon-γ, colony stimulating factors, interleukins -3, -4, -5 and -13, eotaxin and transforming growth factor-β. Substances that down-regulate LT generation include adenosine, nitric oxide, prostaglandin E₂, lipoxins and 15-hydroxyeicosatetraenoic acid. Certain substances are capable of either augmenting or attenuating LT biosynthesis, depending on the circumstances. For example, short-term exposure to lipopolysaccharide enhances LT synthesis, whereas longer exposures can be inhibitory. Likewise, low concentrations of oxidants often augment synthesis, while high concentrations inhibit synthesis. Pre-treatment with glucocorticoids can inhibit, enhance or have no effect on LT biosynthesis. Results with glucocorticoids

Correspondence: Professor M. Peters-Golden, Division of Pulmonary and Critical Care Medicine, University of Michigan Health System, 6301, MSRB III, 1150 West Medical Center Drive, Ann Arbor Michigan, MI 48109-0642, USA.
Fig. 1. Intracellular compartmentalization of steps involved in LT biosynthesis. Gaps in the nuclear envelope represent nuclear pores. Solid arrows and filled arrowheads represent translocation of proteins to the nuclear envelope. Dashed lines indicate shuttling of proteins through nuclear pores. Solid lines with unfilled arrowheads represent the generation and flow of metabolic intermediates. Abbreviations: Ca\(^{2+}\), calcium; cPLA\(_2\), cytosolic phospholipase A\(_2\); AA, arachidonic acid; 5-LO, 5-lipoxygenase; FLAP, 5-LO activating protein; LTA\(_{4}\)H, LTA\(_{4}\) hydrolase; LTC\(_{4}\)S, LTC\(_{4}\) synthase.

seem to depend on the cell type, the species under investigation and whether exposure is *in vitro* or *in vivo*; even under a given set of experimental conditions, conflicting results have been observed.

The mechanisms underlying modulation of LT synthetic capacity by these and other substances are not clear in all instances. It is obvious that, like other cellular responses, agonist-stimulated LT synthesis will depend on the concentration of agonist, the number of agonist receptors present, and the amplitude of signal transduction events that couple receptor ligation to generation of the second messengers (such as Ca\(^{2+}\) and diacylglycerol) necessary to initiate the LT biosynthetic pathway. In addition, the metabolic capacity of a leucocyte can be influenced by the cellular composition of its milieu, as occurs with transcellular processing of metabolic intermediates such as AA or LTA\(_{4}\). Finally, the availability of AA for conversion to LTs can be regulated by dietary modifications of fatty acid intake that alter the arachidonate content of phospholipids.

For the remainder of this discussion, the focus will be on the key LT-forming proteins as potential loci for regulatory control. Examples are certainly recognized in which regulation occurs at the level of phospholipid hydrolysis, at the 5-LO/FLAP step, or at one of the terminal steps (e.g. LTC\(_{4}\) synthase). As a conceptual framework, it is useful to consider four general means by which each of these enzymatic steps can be regulated (see Table 1):

1. the availability of small molecule cofactors necessary for optimal enzyme activity;
2. post-translational modifications that alter catalytic activity;
3. transcriptional or translational events that affect the steady-state levels of proteins;
4. intracellular compartmentalization of these proteins.

**Enzyme cofactors**

The availability of small molecule cofactors (Ca\(^{2+}\), ATP and reduced glutathione) can be an important determinant of the actions of LT-forming enzymes. Both the cPLA\(_2\) and 5-LO enzymes have a dual requirement for Ca\(^{2+}\); namely, to initiate their translocation to the nuclear envelope and for maximal catalytic efficiency. The actions of these enzymes are therefore critically dependent on the local intracellular Ca\(^{2+}\) concentration. Optimal 5-LO activity also requires ATP. Cellular ATP content is of obvious central importance for cell homeostasis, and is affected by many environmental stressors. Thus, reduced ATP content following exposure to oxidants or high concentrations of unsaturated fatty acids has been shown to mediate impairment in 5-LO
metabolic capacity [2]. Finally, reduced glutathione is an essential cosubstrate for the formation of LTC₄, and changes in the level of glutathione have been shown to modulate the capacity for LTC₄ synthesis in vitro and in vivo [3]. In fact, glutathione levels influence the relative conversion of LTA₄ to either LTC₄ or LTB₄. Since reduced glutathione content reflects the overall level of oxidant stress and can vary among tissues, it, like ATP, is probably a ubiquitous determinant of LT generation.

Post-translational alterations of enzyme activity

The catalytic activities of some of the LT-synthesizing enzymes can be rapidly modulated by post-translational modifications of existing protein molecules. The best recognized of these modifications is phosphorylation, mediated by various protein kinases. For example, phosphorylation of cPLA₂ on serine 505 by either protein kinase C or mitogen-activated protein kinase increases its catalytic efficiency [4]. Recently, phosphorylation of 5-LO by mitogen-activated protein kinase-activated protein kinases has been demonstrated, with an associated increase in enzyme activity [5]. Indeed, it is likely that the ability of many agonists (e.g. phorbol esters, lipopolysaccharide and various cytokines) to rapidly ‘prime’ cells for enhanced AA release and LT synthesis in response to low concentrations of a second agonist, reflects their activation of kinases that phosphorylate cPLA₂ and/or 5-LO. However, it is equally likely that the ability of certain substances to suppress AA release and LT synthesis reflects their ability to inhibit such stimulatory kinase cascades: an example is the increased levels of the inhibitory messenger, cyclic AMP, induced by adenosine and prostaglandin E₂ [6].

An opposing example to cPLA₂ and 5-LO is provided by LTC₄ synthase, whose catalytic activity has been shown to be reduced by phosphorylation by protein kinase C [7]. Although many other types of post-translational modifications of proteins are recognized, their contributions to regulation of the enzymes involved in LT synthesis remain to be demonstrated. However, our laboratory has recently obtained preliminary evidence that the 5-LO protein can be nitrotyrosinated by peroxynitrite, with a concomitant reduction of enzyme activity.

Table 1. Mechanisms regulating actions of LT-forming proteins

<table>
<thead>
<tr>
<th>Mechanism</th>
<th>cPLA₂</th>
<th>5-LO</th>
<th>FLAP</th>
<th>LTC₄S</th>
<th>LTA₄H</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cofactors</td>
<td>yes</td>
<td>yes</td>
<td>no</td>
<td>yes</td>
<td>no</td>
</tr>
<tr>
<td>Catalytic activity</td>
<td>yes</td>
<td>yes</td>
<td>no</td>
<td>yes</td>
<td>?</td>
</tr>
<tr>
<td>Expression level</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
</tr>
<tr>
<td>Compartimentalization</td>
<td>yes</td>
<td>yes</td>
<td>no</td>
<td>yes</td>
<td>yes</td>
</tr>
</tbody>
</table>

Abbreviations are as defined in the legend to Fig. 1.

Alterations in steady-state enzyme protein levels

A second type of priming or enhancement of LT synthesis occurs when the steady-state levels of key enzyme proteins are increased. As this requires new protein translation, it is a delayed response that typically manifests over a number of hours. Examples of this form of regulation encompass all types of myeloid cells, including macrophages/monocytes, neutrophils, eosinophils, basophils and mast cells. Increases in levels of all of the LT-forming proteins have been reported. A wide spectrum of substances and experimental circumstances has been identified to induce such responses. Induction of these proteins is often, but not always, co-ordinated. Thus, 5-LO and/or FLAP expression were increased with macrophage differentiation as well as exposure to vitamin D₃ and glucocorticoids [8]. Similar results were observed with exposure to CD4 lymphocyte conditioned medium [8] and pulmonary alveolar lining fluid: in these latter circumstances, cytokines probably account for much of the observed effect. Indeed, cytokines have been the most extensively investigated substances in this regard. Cytokines that have been shown to increase expression of one or more of the LT-forming proteins include colony-stimulating factors, tumour necrosis factor-α, interleukins -1, -3, -4 and -5, and transforming growth factor-β [8–11]. It is likely that amplification of LT biosynthesis by cytokine circuits is an important factor in the pathogenesis of inflammatory diseases such as asthma.

As would be expected, expression of LT-forming proteins can also be reduced below normal baseline levels. In contrast to their effects on 5-LO and FLAP, glucocorticoids can inhibit expression of cPLA₂ as well as sPLA₂. Perhaps some of the conflicting findings on glucocorticoid effects are due to these opposing actions on AA availability vs. 5-lipoxygenation. I am aware of no other examples of diminished enzyme expression within the 5-LO pathway caused by the presence of a suppressive factor. However, decreases in macrophage LT synthetic capacity as well as expression of 5-LO and/or FLAP have been observed in animal models characterized by deprivation of certain of the inducing factors listed above. These include dietary vitamin D₃-deficiency [12], targeted deletion of the granulocyte...
macrophage-colony stimulating factor gene [13], and depletion of CD4 lymphocytes using a monoclonal antibody [14]. These results demonstrate the physiological relevance of such regulatory interactions. The clinical relevance of these interactions can be seen in HIV infection, where deficiency of CD4 lymphocyte-derived cytokines results in reductions in 5-LO and especially FLAP protein expression that underlie a dramatic impairment in leucocyte LT synthetic capacity [15].

Although precedent exists for post-transcriptional mechanisms, transcriptional regulation appears to be the dominant means by which the expression of LT-forming proteins is controlled. Analysis of the promoter regions of the genes encoding each of the LT-forming proteins has already revealed some of the known cis elements that mediate transcription factor interactions. Genetic polymorphisms in the promoter regions of some of these genes have also been described [16]. These include a mutation in the 5-LO promoter that modestly reduces its transcriptional activity, and one in the LTC₄ synthase promoter that has been variably linked with aspirin-sensitive asthma and diminished transcriptional activity. A more complete understanding of the role of genetic variation in expression of these proteins under different circumstances will be an important objective of future studies.

**Intracellular compartmentalization of proteins**

As translocation of 5-LO to the nuclear envelope seems to be critical for enzyme action, this step represents another potential locus for regulatory control. Indeed, some agonists that act as priming agents appear to enhance LT synthesis, at least in part, by enhancing 5-LO translocation. Such a mechanism has been observed for lipopolysaccharide [17] and protein kinase C activators. This type of modulation likely entails facilitation of molecular interactions between motifs within 5-LO and structural components of the cell that result from phosphorylation reactions. Inhibition of translocation may likewise emerge as an important regulatory mechanism: in this regard, glucocorticoids have been suggested to inhibit translocation of cPLA₂ [18].

It has become apparent that in resting leukocytes, 5-LO can exist in soluble pools within both the cytosol and the nucleus (reviewed in [1]). Its intracellular locale can vary in a cell-specific fashion. Moreover, within a given cell type, 5-LO can shuttle into and out of the nucleus. Both cytosolic and intranuclear pools of enzyme are capable of translocating to the nuclear envelope upon agonist activation [1]. How do these shifts in intracellular distribution of 5-LO in resting cells influence the capacity for LT synthesis once activation occurs? Depending on the cell type and the experimental circumstance, LT synthetic capacity can be either enhanced or abrogated by nuclear import of 5-LO. Three general mechanisms may explain such effects. First, different 5-LO pools have different capacities to translocate to the nuclear envelope in response to agonist stimulation. Compartment-specific differences in enzyme translocatability may reflect differences in the distribution of critical protein kinases or molecules that act as chaperones or anchors for 5-LO. Second, the topographic distribution of 5-LO relative to the distribution of its endogenous inhibitors may affect enzyme action. Third, the access of 5-LO-derived LTA₄ to downstream enzymes such as LTA₄ hydrolase will be influenced by the proximity of the two enzymes. Alveolar macrophages, which have a higher capacity for LT synthesis than do other tissue macrophages, illustrate all of these phenomena.

Their prominent intranuclear pool of 5-LO readily translocates to the nuclear envelope, whereas their cytosolic pool does not.

This intranuclear pool of enzyme would be segregated from the endogenous inhibitor identified in the cytosol of these cells [19,20]. In contrast to some other cell types, the alveolar macrophage has a prominent intranuclear pool of LTA₄ hydrolase: this facilitates efficient coupling of these two sequential reactions at the nucleoplasmic face of the inner nuclear membrane.

Although intracellular compartmentalization has emerged as an important means of regulating the output of the 5-LO pathway, many issues remain to be clarified. These include the molecular mechanisms mediating compartmentalization, the actions of LTs in different intracellular compartments, and the role that alterations in compartmentalization may play in disease states.

**References**


5 Werz O, Klemm J, Samuelsson B, Radmark O. 5-Lipoxygenase is phosphorylated by p38 kinase-dependent
6 Flaman D, Boudreault S, Picard S et al. Adenosine a
potent natural suppressor of arachidonic acid release and 
leukotriene biosynthesis in human neutrophils. Am J 
Respir Crit Care Med 2000; 161:S88–S94.
7 Gupta N, Nicholson D, Ford-Hutchinson A. Demonstra-
tion of cell-specific phosphorylation of LTC4 synthase.
8 Bigby T. Regulation of expression of the 5-lipoxygenase 
9 Pouliot M, McDonald P, Borgeat P, McColl S. Granulo-
cyte/macrophage colony-stimulating factor stimulates the 
expression of the 5-lipoxygenase-activating protein (FLAP) 
10 Steinhilber D, Radmark O, Samuelsson B. Transforming 
growth factor β upregulates 5-lipoxygenase activity during 
myeloid maturation. Proc Natl Acad Sci USA 1993;
90:5984–8.
11 Cowburn A, Holgate S, Sampson A. IL-5 increases 
expression of 5-lipoxygenase-activating protein and trans-
locates 5-lipoxygenase to the nucleus in human blood 
12 Coffey MJ, Wilcoxen SE, Phare SM, Simpson RU, Gyetko 
MR, Peters-Golden M. Reduced 5-lipoxygenase metabo-
ism of arachidonic acid in macrophages from 1,25-
dihydroxyvitamin D3-deficient rats. Prostaglandins 1994;
13 Moore B, Coffey M, Christensen P et al. GM-CSF 
regulates bleomycin-induced pulmonary fibrosis via a 
14 Coffey M, Phare S, Peters-Golden M, Huffnagle G. 
Regulation of 5-lipoxygenase metabolism in mononuclear 
phagocytes by CD4 T lymphocytes. Exp Lung Res 1999;
15 Coffey M, Phare S, George S, Peters-Golden M, Kazanjian 
P. Granulocyte colony-stimulating factor administration to 
HIV-infected subjects augments reduced leukotriene syn-
thesis and anticryptococcal activity in neutrophils. J Clin 
Invest 1998; 102:663–70.
16 In K, Asano K, Beier D et al. Naturally occurring 
mutations in the human 5-lipoxygenase gene promoter 
that modify transcription factor binding and reporter gene 
17 Surette M, Dallaire N, Jean N, Picard S, Borgeat P. 
Mechanisms of the priming effect of lipopolysaccharides 
on the biosynthesis of leukotriene B4 in chemotactic 
peptide-stimulated human neutrophils. FASEB J 1998;
18 Sano A, Munoz N, Sano H et al. Inhibition of ePLA2 
translocation and leukotriene C4 secretion by fluticasone 
propionate in exogenously activated human eosinophils. 
19 Coffey MJ, Wilcoxen SE, Sporn PH, Peters-Golden M. 
Regulation of 5-lipoxygenase activity in mononuclear 
phagocytes: characterization of an endogenous cytosolic 
inhibitor. Prostaglandins Other Lipid Med 1998;
56:103–17.
20 Straif D, Kellner R, Bahr U, Steinhilber D. Glutathione 
peroxidase-1 but not -4 is involved in the regulation of 
cellular 5-lipoxygenase activity in monocytic cells. Biochem 